Bystander suppression of experimental arthritis by nasal administration of a heat shock protein peptide

Annals of the Rheumatic Diseases

Volumn 70, Issue 12, 2011, Pages 2199-2206

  Zonneveld Huijssoon, Evelien ^a   Roord, Sarah T A ^a   De Jager, Wilco ^a   Klein, Mark ^a   Albani, Salvatore ^b,c   Anderton, Stephen M ^d   Kuis, Wietse ^a   Van Wijk, Femke ^a   Prakken, Berent J ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b EUREKA Institute for Translational Medicine   (Italy)

^c BURNHAM INSTITUTE   (United States)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; GAMMA INTERFERON; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 60[280-294]; HEAT SHOCK PROTEIN 65[254-268]; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTHRITIS; ARTICLE; BYSTANDER EFFECT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IN VITRO STUDY; INFLAMMATION; LYMPH NODE; LYMPHOCYTE TRANSFER; MALE; MUCOSA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; SPLEEN;

ADMINISTRATION, INTRANASAL; ANIMALS; ARTHRITIS, EXPERIMENTAL; BYSTANDER EFFECT; CD4-POSITIVE T-LYMPHOCYTES; CHAPERONIN 60; CYTOKINES; EPITOPES, T-LYMPHOCYTE; FREUND'S ADJUVANT; IMMUNITY, MUCOSAL; IMMUNOTHERAPY, ADOPTIVE; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; MALE; PEPTIDE FRAGMENTS; RATS; RATS, INBRED LEW; SPLEEN; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 82755182665     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.136994     Document Type: Article

References (53)

1. Dekker L, Armbrust W, Rademaker CM, et al. Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2004;22:252-8.
2. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101.
3. Prakken BJ, Wendling U, van der Zee R, et al. Induction of IL-10 and inhibition of experimental arthritis are specific features of microbial heat shock proteins that are absent for other evolutionarily conserved immunodominant proteins. J Immunol 2001;167:4147-53.
4. Belogurov AA, Jr, Zargarova TA, Turobov VI, et al. Suppression of ongoing experimental allergic encephalomyelitis in DA rats by novel peptide drug, structural part of human myelin basic protein 46-62. Autoimmunity 2009;42:362-4.
5. Reynolds J, Abbott DS, Karegli J, et al. Mucosal tolerance induced by an immunodominant peptide from rat alpha3(IV)NC1 in established experimental autoimmune glomerulonephritis. Am J Pathol 2009;174:2202-10.
6. Broere F, Wieten L, Klein Koerkamp EI, et al. Oral or nasal antigen induces regulatory T cells that suppress arthritis and proliferation of arthritogenic T cells in joint draining lymph nodes. J Immunol 2008;181:899-906.
7. Zhao J, Li R, He J, et al. Mucosal administration of an altered CII263-272 peptide inhibits collagen-induced arthritis by suppression of Th1/Th17 cells and expansion of regulatory T cells. Rheumatol Int 2008;29:9-16.
8. Every AL, Kramer DR, Mannering SI, et al. Intranasal vaccination with proinsulin DNA induces regulatory CD4+ T cells that prevent experimental autoimmune diabetes. J Immunol 2006;176:4608-15.
9. Souroujon MC, Maiti PK, Feferman T, et al. Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors. Ann N Y Acad Sci 2003;998:533-6.
10. van Eden W, van der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol 2005;5:318-30.
11. Prakken BJ, Samodal R, Le TD, et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci USA 2004;101:4228-33.
12. Massa M, Passalia M, Manzoni SM, et al. Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis Rheum 2007;56:1648-57.
13. Hauet-Broere F, Wieten L, Guichelaar T, et al. Heat shock proteins induce T cell regulation of chronic inflammation. Ann Rheum Dis 2006;65(Suppl 3):iii65-8.
14. Koffeman EC, Genovese M, Amox D, et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum 2009;60:3207-16.
15. Kamphuis S, Kuis W, de Jager W, et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 2005;366:50-6.
16. Anderton SM, van der Zee R, Prakken B, et al. Activation of T cells recognizing self 60-kD heat shock protein can protect against experimental arthritis. J Exp Med 1995;181:943-52.
17. de Graeff-Meeder ER, van Eden W, Rijkers GT, et al. Juvenile chronic arthritis: T cell reactivity to human HSP60 in patients with a favorable course of arthritis. J Clin Invest 1995;95:934-40.
18. Prakken BJ, Roord S, Ronaghy A, et al. Heat shock protein 60 and adjuvant arthritis: a model for T cell regulation in human arthritis. Springer Semin Immunopathol 2003;25:47-63.
19. Prakken BJ, Roord S, van Kooten PJ, et al. Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope. Arthritis Rheum 2002;46:1937-46.
20. Reizis B, Mor F, Eisenstein M, et al. The peptide binding specificity of the MHC class II I-A molecule of the Lewis rat, RT1.BI. Int Immunol 1996;8:1825-32.
21. Wauben MH, van der Kraan M, Grosfeld-Stulemeyer MC, et al. Definition of an extended MHC class II-peptide binding motif for the autoimmune disease-associated Lewis rat RT1.BL molecule. Int Immunol 1997;9:281-90.
22. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 1977;146:857-68.
23. Anderton SM, van der Zee R, Noordzij A, et al. Differential mycobacterial 65-kDa heat shock protein T cell epitope recognition after adjuvant arthritis-inducing or protective immunization protocols. J Immunol 1994;152:3656-64.
24. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001;182:207-14.
25. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
26. Durai M, Gupta RS, Moudgil KD. The T cells specific for the carboxyl-terminal determinants of self (rat) heat-shock protein 65 escape tolerance induction and are involved in regulation of autoimmune arthritis. J Immunol 2004;172:2795-802.
27. Prakken BJ, van der Zee R, Anderton SM, et al. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc Natl Acad Sci USA 1997;94:3284-9.
28. Prakken BJ, van der Zee R, Anderton SM, et al. Tolerance to an arthritogenic T-cell epitope of HSP65 and the regulation of experimental arthritis. Ann N Y Acad Sci 1996;778:425-6.
29. Wendling U, Paul L, van der Zee R, et al. A conserved mycobacterial heat shock protein (HSP) 70 sequence prevents adjuvant arthritis upon nasal administration and induces IL-10-producing T cells that cross-react with the mammalian self-hsp70 homologue. J Immunol 2000;164:2711-17.
30. van Bilsen JH, Wagenaar-Hilbers JP, van der Cammen MJ, et al. Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration. Arthritis Res 2002;4:R2.
31. Bárdos T, Czipri M, Vermes C, et al. Continuous nasal administration of antigen is critical to maintain tolerance in adoptively transferred autoimmune arthritis in SCID mice. Clin Exp Immunol 2002;129:224-31.
32. Derry CJ, Harper N, Davies DH, et al. Importance of dose of type II collagen in suppression of collagen-induced arthritis by nasal tolerance. Arthritis Rheum 2001;44:1917-27.
33. van Tienhoven EA, Broeren CP, Noordzij A, et al. Nasal application of a naturally processed and presented T cell epitope derived from TCR AV11 protects against adjuvant arthritis. Int Immunol 2000;12:1715-21.
34. Higuchi K, Kweon MN, Fujihashi K, et al. Comparison of nasal and oral tolerance for the prevention of collagen induced murine arthritis. J Rheumatol 2000;27:1038-44.
35. Garcia G, Komagata Y, Slavin AJ, et al. Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen. J Autoimmun 1999;13:315-24.
36. Chu CQ, Londei M. Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis. J Autoimmun 1999;12:35-42.
37. Bayrak S, Mitchison NA. Bystander suppression of murine collagen-induced arthritis by long-term nasal administration of a self type II collagen peptide. Clin Exp Immunol 1998;113:92-5.
38. Myers LK, Seyer JM, Stuart JM, et al. Suppression of murine collagen-induced arthritis by nasal administration of collagen. Immunology 1997;90:161-4.
39. Staines NA, Harper N, Ward FJ, et al. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin Exp Immunol 1996;103:368-75.
40. Roord ST, Zonneveld-Huijssoon E, Le T, et al. Modulation of T cell function by combination of epitope specific and low dose anticytokine therapy controls autoimmune arthritis. PLoS ONE 2006;1:e87.
41. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002;2:85-95.
42. de Jong H, Lafeber FF, de Jager W, et al. Pan-DR-binding Hsp60 self epitopes induce an interleukin-10-mediated immune response in rheumatoid arthritis. Arthritis Rheum 2009;60:1966-76.
43. Quintana FJ, Carmi P, Mor F, et al. DNA fragments of the human 60-kDa heat shock protein (HSP60) vaccinate against adjuvant arthritis: identification of a regulatory HSP60 peptide. J Immunol 2003;171:3533-41.
44. Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50.
45. Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004;199:1401-8.
46. Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707-13.
47. Schmidt-Weber CB, Pohlers D, Siegling A, et al. Cytokine gene activation in synovial membrane, regional lymph nodes, and spleen during the course of rat adjuvant arthritis. Cell Immunol 1999;195:53-65.
48. Kelchtermans H, Billiau A, Matthys P. How interferon-gamma keeps autoimmune diseases in check. Trends Immunol 2008;29:479-86.
49. Sawitzki B, Kingsley CI, Oliveira V, et al. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med 2005;201:1925-35.
50. Paul AG, van Kooten PJ, van Eden W, et al. Highly autoproliferative T cells specific for 60-kDa heat shock protein produce IL-4/IL-10 and IFN-gamma and are protective in adjuvant arthritis. J Immunol 2000;165:7270-7.
51. Boccaccio GL, Mor F, Steinman L. Non-coding plasmid DNA induces IFN-gamma in vivo and suppresses autoimmune encephalomyelitis. Int Immunol 1999;11:289-96.
52. van Eden W, Wendling U, Paul L, et al. Arthritis protective regulatory potential of self-heat shock protein cross-reactive T cells. Cell Stress Chaperones 2000;5:452-7.
53. Bresson D, Togher L, Rodrigo E, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006;116:1371-81.